Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women - Scorecard - MDSpire
Advertisement
Feminizing hormone therapy using GnRH agonists as antiandrogens is not associated with adverse metabolic and bone effects in adult transgender women
Clinical Scorecard: The Use of GnRH Agonists in Feminizing Hormone Therapy Does Not Lead to Negative Metabolic or Bone Health Outcomes in Adult Transgender Women
At a Glance
Category
Detail
Condition
Key Mechanisms
GnRH agonists and estrogens in gender-affirming hormone therapy focusing on metabolic and bone health outcomes
Target Population
Care Setting
Key Highlights
Include confidence intervals for all metrics.
Guideline-Based Recommendations
Diagnosis
Consider including specific diagnostic criteria for gender dysphoria.
Management
Outline management strategies based on metabolic and bone health outcomes.
Monitoring & Follow-up
Suggest monitoring frequency for metabolic and bone health.
Risks
Identify potential risks associated with GnRH agonists in this population.
Patient & Prescribing Data
GAHT using GnRH agonists and estrogens does not adversely affect metabolic or bone health outcomes; consider implications for prescribing.
Clinical Best Practices
Specify frequency and methods for assessing bone mineral density.
